Barclays Reiterates an 'Overweight' on ARIAD Pharmaceuticals (ARIA); Ponatinib Demonstrated Acceptable Safety Profile

Article Stock Quotes (1) Comments (0)

Barclays reiterates an 'Overweight' on ARIAD Pharmaceuticals (NASDAQ: ARIA) price target of $20.00.

Analyst, Ying Huang, said, "We attended the presentation of PACE trial data and ARIA management lunch at the annual meeting of American Society of Clinical Oncology (ASCO). We reiterate our rating as we become more confident in the FDA approval of ponatinib."

For an analyst ratings summary and ratings history on ARIAD Pharmaceuticals click here. For more ratings news on ARIAD Pharmaceuticals click here.

Shares of ARIAD Pharmaceuticals closed at $15.63 yesterday, with a 52 week range of $7.55-$17.60.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Morgan Stanley Maintains Bullish Stance on Walter Energy (WLT)
• UPDATE: BofA/Merrill Lynch Downgrades Cliffs Natural Resources (CLF) to Underperform
• Adobe (ADBE) Posts Positive Creative Cloud Subscriber Surprise in Q2 - Jefferies

Create E-mail Alert Related Categories

Analyst Comments, FDA

Related Entities

Barclays

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?